Trial Profile
Pilot trial of sequential dose-dense neoadjuvant chemotherapy plus Herceptin [trastuzumab] in HER2 positive stage II-III breast cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2012 Additioanl lead trial investigator identified as reported by ClinicalTrials.gov.
- 18 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 18 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.